

Curriculum Vitae

Personal information Victor Mangas Sanjuan

Work experience

1. Employer: Miguel Hernandez University
 - Start date: 012012
 - End date: 072014
 - Position: PhD Researcher
 - Activities:
 - Country: Spain
2. Employer: Miguel Hernandez University
 - Start date: 082014
 - End date: 122015
 - Position: Post_Doc Researcher
 - Activities:
 - Country: Spain
3. Employer: University of Navarra
 - Start date: 012016
 - End date: 092016
 - Position: Post_Doc Researcher
 - Activities:
 - Country: Spain
4. Employer: Miguel Hernandez University
 - Start date: 102016
 - End date: 042017
 - Position: Post_Doc Researcher
 - Activities:
 - Country: Spain
5. Employer: University of Valencia
 - Start date: 042017
 - End date: 102022
 - Position: Assistant Professor
 - Activities:
 - Country: Spain
6. Employer: University of Valencia
 - Start date: 102022
 - End date:
 - Position: Associate Professor
 - Activities:
 - Country: Spain

Education and training

1. Subject: Miguel Hernandez University
 - Start date: 092004
 - End date: 092009
 - Qualification: 8.52
 - Organisation: Pharmacy Degree
 - Country: Spain
2. Subject: University of Valencia
 - Start date: 102009
 - End date: 072010
 - Qualification: with honours
 - Organisation: Master on Pharmacokinetics and Pharmaceutical Care
 - Country: Spain
3. Subject: University of Valencia
 - Start date: 092010
 - End date: 072014
 - Qualification: with honours
 - Organisation: PhD Degree on Pharmacy
 - Country: Spain

Additional information

Publications

- 1: Rodriguez-Fernandez K, Gómez-Mantilla JD, Shukla S, Mangas-Sanjuán V, Peters SA. Solubility-Limited Absorption Identified by a Simplified PBPK Model for the Prediction of Positive Food Effect for BCS II/IV Drugs. Clin Pharmacokinet. 2025 Feb 3. doi: 10.1007/s40262-025-01472-w. Epub ahead of print. PMID: 39899202.
- 2: Rodriguez-Fernandez K, Gómez-Mantilla JD, Shukla S, Stopfer P, Sieger P, Mangas-Sanjuán V, Peters SA. Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs. Clin Pharmacokinet. 2025 Feb 3. doi: 10.1007/s40262-025-01473-9. Epub ahead of print. PMID: 39899201.

- 3: Rodríguez-Fernández K, Zarzoso-Foj J, Saez-Bello M, Mateu-Puchades A, Martorell-Calatayud A, Merino-Sanjuan M, Gras-Colomer E, Climente-Martí M, Mangas-Sanjuan V. Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing. *Pharmaceutics*. 2024 Dec 10;16(12):1576. doi: 10.3390/pharmaceutics16121576. PMID: 39771555; PMCID: PMC11678170.
- 4: Varela-Rey I, Bandín-Vilar E, Toja-Camba FJ, Cañizo-Outeiriño A, Cajade-Pascual F, Ortega-Hortas M, Mangas-Sanjuan V, González-Barcia M, Zarra-Ferro I, Mondelo-García C, Fernández-Ferreiro A. Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review. *Antibiotics (Basel)*. 2024 Dec 10;13(12):1203. doi: 10.3390/antibiotics13121203. PMID: 39766593; PMCID: PMC11672403.
- 5: Rodríguez-Fernández K, Zarzoso-Foj J, Saez-Bello M, Mateu-Puchades A, Martorell-Calatayud A, Merino-Sanjuan M, Gras-Colomer E, Climente-Martí M, Mangas-Sanjuan V. Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis. *Pharmaceutics*. 2024 Oct 4;16(10):1295. doi: 10.3390/pharmaceutics16101295. PMID: 39458624; PMCID: PMC11510411.
- 6: Alfosea-Cuadrado GM, Zarzoso-Foj J, Adell A, Valverde-Navarro AA, González-Soler EM, Mangas-Sanjuan V, Blasco-Serra A. Population Pharmacokinetic-Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats. *Pharmaceutics*. 2024 Aug 21;16(8):1101. doi: 10.3390/pharmaceutics16081101. PMID: 39204446; PMCID: PMC11359992.
- 7: Mañez-Asensi A, Hernández MJ, Mangas-Sanjuan V, Salvador A, Merino-Sanjuan M, Merino V. Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study. *Pharmaceutics*. 2024 Jun 1;16(6):749. doi: 10.3390/pharmaceutics16060749. PMID: 38931871; PMCID: PMC11207613.
- 8: Reig-López J, Cuquerella-Gilbert M, Bandín-Vilar E, Merino-Sanjuan M, Mangas-Sanjuan V, García-Arieta A. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers. *Eur J Pharm Biopharm*. 2024 Jun;199:114293. doi: 10.1016/j.ejpb.2024.114293. Epub 2024 Apr 17. PMID: 38641229.
- 9: Bandín-Vilar E, Toja-Camba FJ, Vidal-Millares M, Durán-Maseda MJ, Pou-Álvarez M, Castro-Balado A, Maroñas O, Gil-Rodríguez A, Carracedo Á, Zarra-Ferro I, Soy D, Fernández-Ferreiro A, Mangas-Sanjuan V, Mondelo-García C. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling. *Psychiatry Res*. 2024 Mar;333:115721. doi: 10.1016/j.psychres.2024.115721. Epub 2024 Jan 5. PMID: 38245977.
- 10: Rodríguez-Fernández K, Reynaldo-Fernández G, Reyes-González S, de Las Barreras C, Rodríguez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. *Biomed Pharmacother*. 2024 Jan;170:115977. doi: 10.1016/j.biopha.2023.115977. Epub 2023 Dec 6. PMID: 38056237; PMCID: PMC10853672.
- 11: Cuquerella-Gilbert M, Reig-López J, Serna J, Rueda-Ferreiro A, Merino-Sanjuan M, Mangas-Sanjuan V, Sánchez-Herrero S. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®. *Comput Methods Programs Biomed*. 2024 Jan;243:107929. doi: 10.1016/j.cmpb.2023.107929. Epub 2023 Nov 18. PMID: 38006685.
- 12: Rodríguez-Belenguer P, March-Vila E, Pastor M, Mangas-Sanjuan V, Soria-Olivas E. Usage of model combination in computational toxicology. *Toxicol Lett*. 2023 Nov 1;389:34-44. doi: 10.1016/j.toxlet.2023.10.013. Epub 2023 Oct 27. PMID: 37890682.
- 13: García-Cremades M, Parra-Guillen ZP, Mangas-Sanjuan V, Geerts H. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use. *Front Pharmacol*. 2023 Oct 4;14:1274139. doi: 10.3389/fphar.2023.1274139. PMID: 37860109; PMCID: PMC10582944.
- 14: Sancho-Araiz A, Parra-Guillen ZP, Bragard J, Ardanza S, Mangas-Sanjuan V, Trocóniz IF. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment. *PLoS Comput Biol*. 2023 Oct 4;19(10):e1011507. doi: 10.1371/journal.pcbi.1011507. PMID: 37792732; PMCID: PMC10550146.
- 15: Rodríguez-Belenguer P, Mangas-Sanjuan V, Soria-Olivas E, Pastor M. Integrating Mechanistic and Toxicokinetic Information in Predictive Models of Cholestasis. *J Chem Inf Model*. 2024 Apr 8;64(7):2775-2788. doi: 10.1021/acs.jcim.3c00945. Epub 2023 Sep 3. PMID: 37660324; PMCID: PMC11005038.
- 16: Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, Zarra-Ferro I, González-Barcia M, Campos-Toimil M, Mangas-Sanjuan V, Mondelo-García C, Fernández-Ferreiro A. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid. *Clin Pharmacokinet*. 2023 Sep;62(9):1331. doi: 10.1007/s40262-023-01295-7. Erratum for: *Clin Pharmacokinet*. 2022 Jun;61(6):789-817. doi: 10.1007/s40262-022-01125-2. PMID: 37535241.
- 17: Reig-Lopez J, Tang W, Fernandez-Teruel C, Merino-Sanjuan M, Mangas-Sanjuan V, Boulton DW, Sharma P. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies. *Br J Clin Pharmacol*. 2023 Sep;89(9):2691-2702. doi: 10.1111/bcp.15745. Epub 2023 May 1. PMID: 37055941.
- 18: García-Arieta A, Gordon J, Gwaza L, Merino V, Mangas-Sanjuan V. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union. *Pharmaceutics*. 2023 Feb 10;15(2):601. doi: 10.3390/pharmaceutics15020601. PMID: 36839924; PMCID: PMC9961670.
- 19: Mangas-Sanjuan V, Simón M, González-Rojano E, Ochoa D, Abad-Santos F, Román

- M, Ramos M, Govantes C, García-Arieta A. Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State-A Case Study. *Pharmaceutics*. 2023 Jan 26;15(2):409. doi: 10.3390/pharmaceutics15020409. PMID: 36839731; PMCID: PMC9963605.
- 20: Reig-López J, Merino-Sanjuan M, García-Arieta A, Mangas-Sanjuán V. A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms. *Biomed Pharmacother*. 2022 Dec;156:113914. doi: 10.1016/j.biopha.2022.113914. Epub 2022 Oct 26. PMID: 36306592.
- 21: García-Martínez T, Bellés-Medall MD, García-Cremades M, Ferrando-Piqueres R, Mangas-Sanjuán V, Merino-Sanjuan M. Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment. *Pharmaceutics*. 2022 Oct 18;14(10):2226. doi: 10.3390/pharmaceutics14102226. PMID: 36297661; PMCID: PMC9607246.
- 22: Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, Zarra-Ferro I, González-Barcia M, Campos-Toimil M, Mangas-Sanjuan V, Mondelo-García C, Fernández-Ferreiro A. A Review of Population Pharmacokinetic Analyses of Linezolid. *Clin Pharmacokinet*. 2022 Jun;61(6):789-817. doi: 10.1007/s40262-022-01125-2. Epub 2022 Jun 14. Erratum in: *Clin Pharmacokinet*. 2023 Sep;62(9):1331. doi: 10.1007/s40262-023-01295-7. PMID: 35699914; PMCID: PMC9192929.
- 23: McAllister M, Flanagan T, Cole S, Abend A, Kotzagiorgis E, Limberg J, Mead H, Mangas-Sanjuan V, Dickinson PA, Moir A, Pepin X, Zhou D, Tistaert C, Dokoumetzidis A, Anand O, Le Merdy M, Turner DB, Griffin BT, Darwich A, Dressman J, Mackie C. Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. *Pharmaceutics*. 2022 May 7;14(5):1010. doi: 10.3390/pharmaceutics14051010. PMID: 35631595; PMCID: PMC9148161.
- 24: Rodríguez-Fernández K, Gras-Colomer E, Climente-Martí M, Mangas-Sanjuán V, Merino-Sanjuán M. Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics. *Eur J Pharm Sci*. 2022 Jul 1;174:106198. doi: 10.1016/j.ejps.2022.106198. Epub 2022 Apr 30. PMID: 35504449.
- 25: Rodríguez-Fernández K, Mangas-Sanjuán V, Merino-Sanjuán M, Martorell-Calatayud A, Mateu-Puchades A, Climente-Martí M, Gras-Colomer E. Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. *Pharmaceutics*. 2022 Mar 16;14(3):654. doi: 10.3390/pharmaceutics14030654. PMID: 35336028; PMCID: PMC8954607.
- 26: Gras-Colomer E, Mangas-Sanjuán V, Martínez-Gómez MA, Climente-Martí M, Merino-Sanjuan M. Quantitative assessment of the exposure-efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy. *Br J Clin Pharmacol*. 2022 Jun;88(6):2727-2737. doi: 10.1111/bcp.15198. Epub 2022 Jan 10. PMID: 34957594.
- 27: Sancho-Araiz A, Zalba S, Garrido MJ, Berraondo P, Topp B, de Alwis D, Parra-Guillen ZP, Mangas-Sanjuan V, Trocóniz IF. Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. *Cancers (Basel)*. 2021 Oct 9;13(20):5049. doi: 10.3390/cancers13205049. PMID: 34680196; PMCID: PMC8534053.
- 28: Xu Z, Merino-Sanjuan M, Mangas-Sanjuan V, García-Arieta A. Estimators and confidence intervals of $f_{sub>2</sub>}$ using bootstrap methodology for the comparison of dissolution profiles. *Comput Methods Programs Biomed*. 2021 Nov;212:106449. doi: 10.1016/j.cmpb.2021.106449. Epub 2021 Oct 2. PMID: 34644663.
- 29: Sancho-Araiz A, Mangas-Sanjuan V, Trocóniz IF. The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. *Pharmaceutics*. 2021 Jul 2;13(7):1016. doi: 10.3390/pharmaceutics13071016. PMID: 34371708; PMCID: PMC8309057.
- 30: Toja-Camba FJ, Gesto-Antelo N, Maroñas O, Echarri Arrieta E, Zarra-Ferro I, González-Barcia M, Bandín-Vilar E, Mangas Sanjuan V, Facal F, Arrojo Romero M, Carracedo A, Mondelo-García C, Fernández-Ferreiro A. Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. *Pharmaceutics*. 2021 Jun 23;13(7):935. doi: 10.3390/pharmaceutics13070935. PMID: 34201784; PMCID: PMC8308912.
- 31: Reig-López J, García-Arieta A, Mangas-Sanjuán V, Merino-Sanjuán M. Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. *Pharmaceutics*. 2021 May 13;13(5):709. doi: 10.3390/pharmaceutics13050709. PMID: 34068030; PMCID: PMC8152487.
- 32: Santiago D, Mangas-Sanjuan V, Melin K, Duconge J, Zhao W, Venkataramanan R. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. *Pharmaceutics*. 2020 Dec 18;12(12):1226. doi: 10.3390/pharmaceutics12121226. PMID: 33352843; PMCID: PMC7766849.
- 33: Xu Z, Mangas-Sanjuán V, Merino-Sanjuán M, Merino V, García-Arieta A. Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms. *Pharmaceutics*. 2020 Nov 28;12(12):1159. doi: 10.3390/pharmaceutics12121159. PMID: 33260792; PMCID: PMC7760601.
- 34: Castro-Suárez N, Trame MN, Ramos-Suzarte M, Dávalos JM, Bacallao-Mendez RA, Maceo-Sinabele AR, Mangas-Sanjuán V, Reynaldo-Fernández G, Rodríguez-Vera L. Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. *Pharmaceutics*. 2020 Nov 26;12(12):1147. doi: 10.3390/pharmaceutics12121147. PMID: 33256255; PMCID: PMC7760646.
- 35: Reig-López J, Maldonado MDM, Merino-Sanjuan M, Cruz-Collazo AM, Ruiz-

- Calderón JF, Mangas-Sanjuán V, Dharmawardhane S, Duconge J. Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. *Pharmaceutics*. 2020 Oct 15;12(10):975. doi: 10.3390/pharmaceutics12100975. PMID: 33076517; PMCID: PMC7602742.
- 36: Michaleas S, Penninga E, Hovgaard D, Dalseg AM, Rosso A, Sarac SB, Jimenez JC, Fernández LL, Fernández CP, Mangas-Sanjuan V, Garcia I, Payares-Herrera C, Sancho-López A, Enzmann H, de Castro Lopes Silva MSS, Duarte S, Pignatti F. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma. *Oncologist*. 2020 Dec;25(12):1067-1074. doi: 10.1002/onco.13554. Epub 2020 Oct 16. PMID: 33026700; PMCID: PMC7938407.
- 37: Sáez-Belló M, Mangas-Sanjuán V, Martínez-Gómez MA, López-Montenegro Soria MÁ, Clemente-Martí M, Merino-Sanjuán M. Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. *Br J Clin Pharmacol*. 2021 Mar;87(3):905-915. doi: 10.1111/bcp.14441. Epub 2020 Jul 8. PMID: 32559325.
- 38: Mangas-Sanjuán V, Pleguezuelos-Villa M, Merino-Sanjuán M, Hernández MJ, Nacher A, García-Arieta A, Peris D, Hidalgo I, Soler L, Sallan M, Merino V. Erratum: Mangas-Sanjuán, V.; et al. Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. *Pharmaceutics*. 2019 Oct 1;11(10):E503. doi: 10.3390/pharmaceutics11100503. PMID: 32397352; PMCID: PMC7284369.
- 39: Noce L, Gwaza L, Mangas-Sanjuan V, Garcia-Arieta A. Comparison of free software platforms for the calculation of the 90% confidence interval of $f_{2,similarity}$ factor by bootstrap analysis. *Eur J Pharm Sci*. 2020 Apr 15;146:105259. doi: 10.1016/j.ejps.2020.105259. Epub 2020 Feb 10. PMID: 32058055.
- 40: Reig-Lopez J, Merino-Sanjuan M, Mangas-Sanjuan V, Prado-Velasco M. A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokinetic model. *Comput Methods Programs Biomed*. 2020 Jun;189:105322. doi: 10.1016/j.cmpb.2020.105322. Epub 2020 Jan 9. PMID: 31954235.
- 41: Mangas-Sanjuán V, Pleguezuelos-Villa M, Merino-Sanjuán M, Hernández MJ, Nacher A, García-Arieta A, Peris D, Hidalgo I, Soler L, Sallan M, Merino V. Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. *Pharmaceutics*. 2019 Oct 1;11(10):503. doi: 10.3390/pharmaceutics11100503. Erratum in: *Pharmaceutics*. 2020 May 09;12(5):E436. doi: 10.3390/pharmaceutics12050436. PMID: 31581492; PMCID: PMC6835722.
- 42: García-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, Mondelo-García C, Maroñas O, Mangas-Sanjuan V, González-Barcia M, Zarra-Ferro I, Aguiar P, Otero-Espinar FJ, Fernández-Ferreiro A. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. *Pharmaceutics*. 2019 Jul 31;11(8):365. doi: 10.3390/pharmaceutics11080365. PMID: 31370346; PMCID: PMC6723750.
- 43: Marques MR, Garcia-Robles A, Usach I, Vento M, Poveda JL, Peris JE, Mangas-Sanjuan V. Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule. *Acta Paediatr*. 2020 Feb;109(2):300-308. doi: 10.1111/apa.14944. Epub 2019 Aug 22. PMID: 31336401.
- 44: Reynaldo-Fernández G, Solozábal J, Amaro D, Fernández-Sánchez EM, Rodríguez-Vera L, Bermejo M, Mangas-Sanjuan V, Troconiz IF. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits. *Eur J Pharm Sci*. 2018 Jul 30;120:123-132. doi: 10.1016/j.ejps.2018.04.047. Epub 2018 May 2. PMID: 29729414.
- 45: Parra-Guillen ZP, Mangas-Sanjuan V, Garcia-Cremades M, Troconiz IF, Mo G, Pitou C, Iversen PW, Wallin JE. Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. *J Pharmacol Exp Ther*. 2018 Jul;366(1):96-104. doi: 10.1124/jpet.118.248286. Epub 2018 Apr 24. PMID: 29691287.
- 46: González-García I, García-Arieta A, Merino-Sanjuan M, Mangas-Sanjuan V, Bermejo M. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation. *Eur J Pharm Sci*. 2018 Jul 1;119:200-207. doi: 10.1016/j.ejps.2018.04.025. Epub 2018 Apr 20. PMID: 29680456.
- 47: Mangas-Sanjuan V, Navarro-Fontestad C, García-Arieta A, Trocóniz IF, Bermejo M. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. *Eur J Pharm Sci*. 2018 May 30;117:193-203. doi: 10.1016/j.ejps.2018.02.014. Epub 2018 Feb 13. PMID: 29452210.
- 48: González-García I, Mangas-Sanjuan V, Merino-Sanjuán M, Álvarez-Álvarez C, Díaz-Garzón Marco J, Rodríguez-Bonnín MA, Langguth T, Torrado-Durán JJ, Langguth P, García-Arieta A, Bermejo M. IVIVC approach based on carbamazepine bioequivalence studies combination. *Pharmazie*. 2017 Aug 1;72(8):449-455. doi: 10.1691/ph.2017.7011. PMID: 29441903.
- 49: Manolis E, Brogren J, Cole S, Hay JL, Nordmark A, Karlsson KE, Lentz F, Benda N, Wangorsch G, Pons G, Zhao W, Gigante V, Serone F, Standing JF, Dokoumetzidis A, Vakkilainen J, van den Heuvel M, Mangas Sanjuan V, Taminiau J, Kerwash E, Khan D, Musuamba FT, Skottheim Rusten I; EMA Modelling and Simulation Working Group. Commentary on the MID3 Good Practices Paper. *CPT Pharmacometrics Syst Pharmacol*. 2017 Jul;6(7):416-417. doi: 10.1002/psp4.12223. Epub 2017 Jul 22. PMID: 28653481; PMCID: PMC5529732.
- 50: Pérez-Castelló I, Mangas-Sanjuan V, González-García I, Gonzalez-Alvarez I, Bermejo M, Marco-Garbayo JL, Trocóniz IF. Population pharmacokinetic model of lithium and drug compliance assessment. *Eur Neuropsychopharmacol*. 2016 Dec;26(12):1868-1876. doi: 10.1016/j.euroneuro.2016.11.005. Epub 2016 Nov 16. PMID: 27865605.

- 51: Shimizu S, den Hoedt SM, Mangas-Sanjuan V, Cristea S, Geuer JK, van den Berg DJ, Hartman R, Bellanti F, de Lange EC. Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat. *Drug Metab Dispos*. 2017 Feb;45(2):152-159. doi: 10.1124/dmd.116.072306. Epub 2016 Nov 11. PMID: 27836941.
- 52: Mangas-Sanjuan V, Colon-Useche S, Gonzalez-Alvarez I, Bermejo M, Garcia-Arieta A. Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. *AAPS J*. 2016 Nov;18(6):1550-1561. doi: 10.1208/s12248-016-9971-5. Epub 2016 Aug 29. PMID: 27571779.
- 53: Bermejo M, Mangas-Sanjuan V, Gonzalez-Alvarez I, Gonzalez-Alvarez M. Enhancing Oral Absorption of β -Lapachone: Progress Till Date. *Eur J Drug Metab Pharmacokinet*. 2017 Feb;42(1):1-10. doi: 10.1007/s13318-016-0369-7. PMID: 27538882.
- 54: Mangas-Sanjuan V, Pastor JM, Rengelshausen J, Bursi R, Troconiz IF. Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects. *Br J Clin Pharmacol*. 2016 Jul;82(1):92-107. doi: 10.1111/bcp.12921. Epub 2016 Apr 14. PMID: 26924818; PMCID: PMC4917809.
- 55: Mangas-Sanjuan V, Gutiérrez-Nieto J, Echezarreta-López M, González-Álvarez I, González-Álvarez M, Casabó VG, Bermejo M, Landin M. Intestinal Permeability of β -Lapachone and Its Cyclodextrin Complexes and Physical Mixtures. *Eur J Drug Metab Pharmacokinet*. 2016 Dec;41(6):795-806. doi: 10.1007/s13318-015-0310-5. PMID: 26602766.
- 56: Colón-Useche S, González-Álvarez I, Mangas-Sanjuan V, González-Álvarez M, Pastoriza P, Molina-Martínez I, Bermejo M, García-Arieta A. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. *Mol Pharm*. 2015 Sep 8;12(9):3167-74. doi: 10.1021/acs.molpharmaceut.5b00076. Epub 2015 Aug 26. PMID: 26287948.
- 57: Garcia-Arieta A, Gordon J, Gwaza L, Mangas-Sanjuan V, Álvarez C, Torrado JJ. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexametoprol Tablets. *Mol Pharm*. 2015 Sep 8;12(9):3194-201. doi: 10.1021/acs.molpharmaceut.5b00131. Epub 2015 Aug 10. PMID: 26237401.
- 58: Oltra-Noguera D, Mangas-Sanjuan V, González-Álvarez I, Colon-Useche S, González-Álvarez M, Bermejo M. Drug gastrointestinal absorption in rat: Strain and gender differences. *Eur J Pharm Sci*. 2015 Oct 12;78:198-203. doi: 10.1016/j.ejps.2015.07.021. Epub 2015 Jul 28. PMID: 26225436.
- 59: Friks M, Fernández-Gallardo J, Gonzalo O, Mangas-Sanjuan V, González-Álvarez M, Serrano del Valle A, Hu C, González-Álvarez I, Bermejo M, Marzo I, Contel M. Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. *J Med Chem*. 2015 Aug 13;58(15):5825-41. doi: 10.1021/acs.jmedchem.5b00427. Epub 2015 Jul 22. PMID: 26147404; PMCID: PMC4538566.
- 60: González-García I, Mangas-Sanjuán V, Merino-Sanjuán M, Bermejo M. In vitro-in vivo correlations: general concepts, methodologies and regulatory applications. *Drug Dev Ind Pharm*. 2015;41(12):1935-47. doi: 10.3109/03639045.2015.1054833. Epub 2015 Jul 2. PMID: 26133085.
- 61: Mangas-Sanjuan V, Buil-Bruna N, Garrido MJ, Soto E, Trocóniz IF. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules. *J Pharmacol Exp Ther*. 2015 Jul;354(1):55-64. doi: 10.1124/jpet.115.223776. Epub 2015 May 6. PMID: 25948593.
- 62: Cuesta-Gragera A, Navarro-Fontestad C, Mangas-Sanjuan V, González-Álvarez I, García-Arieta A, Trocóniz IF, Casabó VG, Bermejo M. Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. *Eur J Pharm Sci*. 2015 Jul 10;74:86-94. doi: 10.1016/j.ejps.2015.04.002. Epub 2015 Apr 11. PMID: 25869458.
- 63: Cuesta-Gragera A, Navarro-Fontestad C, Mangas-Sanjuan V, González-Álvarez I, García-Arieta A, Trocóniz IF, Casabó VG, Bermejo M. Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. *Eur J Pharm Sci*. 2015 Jun 20;73:57-63. doi: 10.1016/j.ejps.2015.03.018. Epub 2015 Apr 2. PMID: 25843043.
- 64: Oltra-Noguera D, Mangas-Sanjuan V, Centelles-Sangüesa A, Gonzalez-Garcia I, Sanchez-Castaño G, Gonzalez-Alvarez M, Casabo VG, Merino V, Gonzalez-Alvarez I, Bermejo M. Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. *J Pharmacol Toxicol Methods*. 2015 Jan-Feb;71:21-32. doi: 10.1016/j.vascn.2014.11.004. Epub 2014 Nov 26. PMID: 25433164.
- 65: Mangas-Sanjuan V, Oláh J, Gonzalez-Alvarez I, Lehotzky A, Tórkési N, Bermejo M, Ovádi J. Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. *Br J Pharmacol*. 2015 Feb;172(3):829-40. doi: 10.1111/bph.12946. Epub 2014 Dec 15. PMID: 25257800; PMCID: PMC4301692.
- 66: Rodríguez-Berna G, Mangas-Sanjuán V, Gonzalez-Alvarez M, Gonzalez-Alvarez I, García-Giménez JL, Díaz Cabañas MJ, Bermejo M, Corma A. A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. *Eur J Med Chem*. 2014 Aug 18;83:366-73. doi: 10.1016/j.ejmech.2014.06.050. Epub 2014 Jun 25. PMID: 24980118.
- 67: Rodriguez-Berna G, Cabañas MJ, Mangas-Sanjuán V, Gonzalez-Alvarez M, Gonzalez-Alvarez I, Abasolo I, Schwartz S Jr, Bermejo M, Corma A. Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives. *ACS Med Chem Lett*. 2013 May 28;4(7):651-5. doi: 10.1021/ml400125z. PMID: 24900725; PMCID: PMC4027458.

68: Mangas-Sanjuan V, González-Álvarez I, González-Álvarez M, Casabó VG, Bermejo M. Modified nonsink equation for permeability estimation in cell monolayers: comparison with standard methods. *Mol Pharm*. 2014 May 5;11(5):1403-14. doi: 10.1021/mp400555e. Epub 2014 Apr 7. PMID: 24665996.

69: Mangas-Sanjuan V, González-Álvarez I, González-Álvarez M, Casabó VG, Bermejo M. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier. *Mol Pharm*. 2013 Oct 7;10(10):3822-31. doi: 10.1021/mp400294x. Epub 2013 Sep 9. PMID: 23977999.

70: Samiei N, Mangas-Sanjuan V, González-Álvarez I, Foroutan M, Shafaati A, Zarghi A, Bermejo M. Ion-pair strategy for enabling amifostine oral absorption: rat in situ and in vivo experiments. *Eur J Pharm Sci*. 2013 Jul 16;49(4):499-504. doi: 10.1016/j.ejps.2013.04.025. Epub 2013 May 2. PMID: 23643735.

71: Fernandez-Teruel C, Mangas-Sanjuan V, Gonzalez-Alvarez I, Ruiz-Garcia A, Casabó VG, Bermejo M. Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. *Xenobiotica*. 2013 Sep;43(9):745-54. doi: 10.3109/00498254.2012.759667. Epub 2013 Jan 8. PMID: 23294363.

72: Gundogdu E, Mangas-Sanjuan V, Gonzalez-Alvarez I, Bermejo M, Karasulu E. In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. *Eur J Drug Metab Pharmacokinet*. 2012 Mar;37(1):65-75. doi: 10.1007/s13318-011-0059-4. Epub 2011 Aug 11. PMID: 21833762.

73: Pham The H, González-Álvarez I, Bermejo M, Mangas Sanjuan V, Centelles I, Garrigues TM, Cabrera-Pérez MÁ. In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. *Mol Inform*. 2011 Apr 18;30(4):376-85. doi: 10.1002/minf.201000118. Epub 2011 Mar 31. PMID: 27466954.

74: Mangas-Sanjuan V, González-Alvarez M, Gonzalez-Alvarez I, Bermejo M. Drug penetration across the blood-brain barrier: an overview. *Ther Deliv*. 2010 Oct;1(4):535-62. doi: 10.4155/tde.10.37. PMID: 22833966.

Projects

Título del proyecto/contrato: Montaje de un laboratorio de química computacional, con fines académicos y científicos, para el diseño racional de nuevos candidatos a fármacos en enfermedades de alto impacto social Tipo de contrato/Programa: Cooperación Iberoamericana Empresa/Administración financiadora: Agencia Española de Cooperación Internacional Número de proyecto/contrato: D/031152/10 Importe: 148.720,00 Duración, desde: 2011 hasta: 2012 Investigador/s responsable/s: Teresa Maria Garrigues Pelufo Número de investigadores participantes: 12 Título del proyecto/contrato: Red_Biofarma. Red para el desarrollo de metodologías biofarmacéuticas racionales que incrementen la competencia y el impacto social de las Industrias farmacéuticas locales Tipo de contrato/Programa: ALFA Empresa/Administración financiadora: Comisión Europea. EuropeAid Oficina de Cooperación Internacional Número de proyecto/contrato: DCI_ALA/10/21_526 Importe: 1.017.034,00 Duración, desde: 2011 hasta: 2014 Investigador/s responsable/s: Maria del Val Bermejo Sanz Número de investigadores participantes: 28 Título del proyecto/contrato: Desarrollo de metodologías biofarmacéuticas racionales para la evaluación de medicamentos transdérmicos en enfermedades crónicas de alta prevalencia Tipo de contrato/Programa: Empresa/Administración financiadora: Universitat de València Número de proyecto/contrato: 2014/13 Importe: 17.000,00 Duración, desde: 2015 hasta: 2016 Investigador/s responsable/s: Virginia Merino Sanjuán Número de investigadores participantes: 15 Título del proyecto/contrato: Medicina personalizada en la degeneración macular asociada a la edad en base a herramientas de Imagen, Farmacocinética y Farmacogenética (ImagePKgen_DMAE) Tipo de contrato/Programa: Empresa/Administración financiadora: Instituto de Salud Carlos III Número de proyecto/contrato: PI17/00940 Importe: 159.720,00 Duración, desde: 2018 hasta: 2021 Investigador/s responsable/s: Francisco Gomez Ulla de Irazabal Número de investigadores participantes: 16 Título del proyecto/contrato: Encapsulación de bicarbonato para la terapia coadyuvante de lipasa pancreática en fibrosis quística Tipo de contrato/Programa: PROGRAMA VLC_BIOMED Empresa/Administración financiadora: Instituto de Investigación Sanitaria La Fe Número de proyecto/contrato: 33_BICAPS_NACHER_RIBES_2 Importe: 4.000,00 Duración, desde: 2018 hasta: 2019 Investigador/s responsable/s: Mª Amparo Nacher Alonso Número de investigadores participantes: 1 Título del proyecto/contrato: Individualización posológica de Glucocerebrosideasa en pacientes Gaucher Tipo I Tipo de contrato/Programa: Empresa/Administración financiadora: Generalitat Valenciana Número de proyecto/contrato: GV/2019/167 Importe: 9.175,00 Duración, desde: 2019 hasta: 2021 Investigador/s responsable/s: Víctor Mangas Sanjuan Número de investigadores participantes: 8 Título del proyecto/contrato: Desarrollo de sistemas biodegradables intraoculares de antiVEGF para el tratamiento de la Degeneración Macular Asociada a la Edad y a Retinopatía Diabética (IMPLADEM) Tipo de contrato/Programa: Empresa/Administración financiadora: MINECO Número de proyecto/contrato: RTI2018_099597_B_I00 Importe: 108.900,00 Duración, desde: 2019 hasta: 2022 Investigador/s responsable/s: Francisco J. Otero Espinar Número de investigadores participantes: 1 Título del proyecto/contrato: Medicina Personalizada para la Optimización del Tratamiento Inmunomodulador en Pacientes con Uveitis (MedPOTIV). Tipo de contrato/Programa: Empresa/Administración financiadora: Instituto de Salud Carlos III Número de proyecto/contrato: PI20/00719 Importe: 92.565,00 Duración, desde: 2021 hasta: 2023 Investigador/s responsable/s: Anxo Fernandez Ferreiro Número de investigadores participantes: 18 Título del proyecto/contrato: Medicina personalizada para la optimización de los tratamientos con antipsicóticos depot en pacientes con esquizofrenia (DEPOTI) Tipo de contrato/Programa: Empresa/Administración financiadora: Sociedad Española de Farmacia Hospitalaria Número de proyecto/contrato: _ Importe: 15.500,00 Duración, desde: 2021 hasta: 2023 Investigador/s responsable/s: Cristina Mondelo García Número de investigadores participantes: 17 Título del proyecto/contrato: Estudio SePKLin: ensayo clínico pragmático, multicéntrico, aleatorizado y controlado en pacientes con Sepsis para evaluar la seguridad y eficacia de la dosificación personalizada PK/PD versus dosificación estándar de Linezolid Tipo de contrato/Programa: Empresa/Administración financiadora: Instituto de Salud Carlos III Número de proyecto/contrato: ICI21/00043 Importe: 273.504,00 Duración, desde: 2022 hasta: 2025 Investigador/s responsable/s: Anxo Fernandez_Ferreiro Número de investigadores participantes: 29

Memberships

Member of the Pharmacokinetics Working Party since 2021 Member of the Modelling and Simulation Working Party since 2017 External assessor of the Spanish Medicine Agency since 2015

Other Relevant Information

RESEARCH STAYS: _Entity: Leiden Academic Centre for Drug Research. City of entity: Leiden, Holland. Start date: 2013. Duration: 5 months. Goals of the stay: Guest. Provable tasks: The influence of P_glycoprotein mediated transport of antipsychotics on the BBB after 7 days of repeated administration _Entity: Universidad de Navarra. City of entity: Pamplona, Spain. Start date: 2014. Duration: 3 months. Goals of the stay: Guest. Provable tasks: Modelos semi_mecanisticos farmacocineticos/farmacodinamicos poblacionales _Entity: Universidad de Navarra. City of entity: Pamplona, Spain. Start date: 2015. Duration: 3 months. Goals of the stay: Guest. Provable tasks: Modelos semi_mecanisticos farmacocineticos/farmacodinamicos poblacionales _Entity: INFECTION, IMMUNITY AND INFLAMMATION, GOS INSTITUTE OF CHILD HEALTH. City of entity: Londres, United Kingdom. Start date: 2018. Duration: 1 month. Goals of the stay: Convocatoria Movilidad PDI_Generalitat Valenciana. Conselleria. de Educacion. Provable tasks: Modelling CD4 T_cell and HIV dynamics in HIV_infected children receiving antiretroviral therapy